|
Index of reports
> Cases with White Blood Cell Count Decreased (33)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Neulasta (Pegfilgrastim) where reactions include white blood cell count decreased. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 33 Next >>
Possible Neulasta side effects in male
Reported by a consumer/non-health professional from United States on 2012-08-16
Patient: male
Reactions: White Blood Cell Count Decreased
Drug(s) suspected as cause:
Neulasta
Dosage: 6 mg, unk
Indication: Chemotherapy
Neupogen
Dosage: unk
Indication: Chemotherapy
Possible Neulasta side effects in 48 year old female
Reported by a consumer/non-health professional from United States on 2012-08-16
Patient: 48 year old female
Reactions: Therapeutic Response Decreased, White Blood Cell Count Decreased, Bone Pain
Drug(s) suspected as cause:
Neupogen
Indication: Chemotherapy
Neulasta
Dosage: 6 mg, unk
Indication: Chemotherapy
Start date: 2011-08-16
Neupogen
Dosage: unk
Indication: Peripheral Blood Stem Cell Apheresis
Start date: 2010-07-01
End date: 2010-08-01
Possible Neulasta side effects in 81 year old male
Reported by a consumer/non-health professional from United States on 2012-08-16
Patient: 81 year old male
Reactions: White Blood Cell Count Decreased, Palpitations, Platelet Count Decreased, Clostridial Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neulasta
Possible Neulasta side effects in female
Reported by a pharmacist from Germany on 2012-08-14
Patient: female
Reactions: White Blood Cell Count Decreased
Drug(s) suspected as cause:
Neulasta
Other drugs received by patient: Gemcitabine Hydrochloride; Cisplatin
Possible Neulasta side effects in 57 year old female
Reported by a physician from United States on 2012-08-09
Patient: 57 year old female, weighing 77.6 kg (170.7 pounds)
Reactions: White Blood Cell Count Decreased, Lymphopenia
Drug(s) suspected as cause:
Velcade
Vincristine Sulfate
Dosage: given on day 4 due to late start of treatment on day 1, cycle 1
Start date: 2008-10-23
End date: 2008-10-23
Rituximab
Cyclophosphamide
Cyclophosphamide
Dosage: 300 mg/m2 over 3 hr, q12hr on days 1-3, treatment carried over to day 4(late start on day 1) cycle 1
Start date: 2008-10-20
End date: 2008-10-23
Dexamethasone
Dosage: 40 mg oral or intravenous on days 1-4, cycle 1
Indication: Mantle Cell Lymphoma
Start date: 2008-10-20
End date: 2008-10-23
Doxorubicin Hydrochloride
Dosage: 25 mg/m2 over 48 hours on days 1-2, cycle 1
Start date: 2008-10-20
End date: 2008-10-22
Doxorubicin Hydrochloride
Dosage: 25 mg/m2 over 48 hours on days 1-2, cycle 2
Indication: Mantle Cell Lymphoma
Start date: 2008-11-10
End date: 2008-11-12
Neulasta
Dosage: on day 5, cycle 2
Indication: Mantle Cell Lymphoma
Start date: 2008-11-14
End date: 2008-11-14
Doxorubicin Hydrochloride
Velcade
Dosage: 1.3 mg/m2 over 3-5 seconds on days 1 and 4, cycle 1
Indication: Mantle Cell Lymphoma
Start date: 2008-11-10
End date: 2008-11-13
Cyclophosphamide
Dosage: 300 mg/m2 over 3 hr, q12hr on days 1-3, treatment carried over to day 4(late start on day 1) cycle 2
Indication: Mantle Cell Lymphoma
Start date: 2008-11-10
End date: 2008-11-13
Vincristine Sulfate
Dosage: given on day 4 due to late start of treatment on day 1, cycle 2
Indication: Mantle Cell Lymphoma
Start date: 2008-11-13
End date: 2008-11-13
Vincristine Sulfate
Dexamethasone
Velcade
Dosage: 1.3 mg/m2 over 3-5 seconds on days 1 and 4, cycle 1
Start date: 2008-10-20
End date: 2008-10-23
Rituximab
Dosage: 375 mg/m2 at 50-400 mg/hour on day 1, cycle 1
Indication: Mantle Cell Lymphoma
Start date: 2008-10-20
End date: 2008-10-20
Rituximab
Dosage: 375 mg/m2 at 50-400 mg/hour on day 1, cycle 2
Start date: 2008-11-10
End date: 2008-11-10
Neulasta
Dexamethasone
Dosage: 40 mg oral or intravenous on days 1-4, cycle 2
Start date: 2008-11-10
End date: 2008-11-13
Neulasta
Dosage: on day 5, cycle 1
Start date: 2008-10-24
End date: 2008-10-24
Possible Neulasta side effects in female
Reported by a physician from Germany on 2012-06-28
Patient: female
Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Neulasta
Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Prednisolone
Dosage: frequency 1 times in 2 week for 5 days
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole
Possible Neulasta side effects in
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-06-27
Patient:
Reactions: Haemoglobin Decreased, White Blood Cell Count Decreased, Haematocrit Decreased, Monocyte Count Decreased, RED Blood Cell Count Decreased, Drug Ineffective, Neutropenic Sepsis
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neulasta
Dosage: 6 mg milligram(s) subcutaneous
Indication: Prophylaxis
Start date: 2011-06-15
Cyclophosphamide
Dosage: 7300 mg milligram(s), intravenous
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Rituxan
Dosage: 650 mg, milligrmam(s), intravenous
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Doxorubicin HCL
Dosage: 85 mg milligram(s) subcutaneous
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Vincristine Sulfate
Dosage: 2 mg milligram(s), unknown intravenous
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Possible Neulasta side effects in female
Reported by a physician from United States on 2012-06-24
Patient: female
Reactions: White Blood Cell Count Decreased, Viral Infection, Pain in Extremity, Dizziness Postural, Adverse Drug Reaction, Pain, Hemiparesis, Fall, Hyperventilation, Death, Myalgia, Arthralgia, Neoplasm Malignant, Vision Blurred, Kidney Infection, Muscle Spasms
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Neupogen
Dosage: unk
Indication: Chemotherapy
Start date: 1996-01-01
Neulasta
Dosage: unk
Indication: Chemotherapy
Start date: 2011-02-01
Other drugs received by patient: Navelbine; Antineoplastic Agents; Xeloda
Possible Neulasta side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-18
Patient: female
Reactions: White Blood Cell Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neupogen
Dosage: unk
Indication: Neutropenia
Start date: 2011-01-01
Neulasta
Indication: Chemotherapy
Start date: 2011-01-01
Other drugs received by patient: Rituxan; Bendamustine
Possible Neulasta side effects in 71 year old male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-04-26
Patient: 71 year old male, weighing 36.2 kg (79.5 pounds)
Reactions: Electrocardiogram ST Segment Depression, White Blood Cell Count Decreased, Blood Urea Increased, Ventricular Hypokinesia, Anaemia, Diastolic Dysfunction, Systolic Dysfunction, Sepsis, Coronary Artery Occlusion, Arteriosclerosis Coronary Artery, Thrombocytopenia, Blood Creatinine Increased, Myocardial Infarction, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neulasta
Dosage: 6 mg milligram(s), subcutaneous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-04-02
Cyclophosphamide
Dosage: 1410 mg milligram(s), intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-03-25
Gemcitabine Hydrochloride
Dosage: 1880 mg milligram(s), intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-04-01
Prednisone TAB
Dosage: 100 mg milligram(s), oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-03-29
(Rituximab)
Dosage: 705 mg milligram(s), intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-03-25
Vincristine Sulfate
Dosage: 2 mg milligram(s), intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-03-25
Other drugs received by patient: Metoclopramide; Tramadol HCL; Cotrim
Possible Neulasta side effects in
Reported by a pharmacist from United States on 2012-04-12
Patient:
Reactions: White Blood Cell Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neulasta
Possible Neulasta side effects in 71 year old male
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-03-30
Patient: 71 year old male, weighing 79.7 kg (175.3 pounds)
Reactions: Electrocardiogram ST Segment Depression, Ventricular Hypokinesia, Platelet Count Increased, Pyrexia, Dyspnoea Exertional, Fatigue, Coronary Artery Occlusion, Chest Pain, Thrombocytopenia, Myocardial Infarction, Blood Creatinine Increased, White Blood Cell Count Decreased, Blood Urea Increased, Anaemia, Coronary Artery Disease, Troponin Increased, Sepsis, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Gemcitabine
Dosage: 1880 mg, intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-04-01
Cyclophosphamide
Dosage: 1410 mg, intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-03-25
Neulasta
Dosage: 6 mg, subcutaneous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-03-29
Vincristine
Dosage: 2 mg, intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-03-25
Rituximab (Rituximab)
Dosage: 705 mg, intravenous
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-03-25
Prednisone TAB
Dosage: 100 mg, oral
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Start date: 2009-03-25
End date: 2009-03-29
Other drugs received by patient: Trimethoprim + Sulfamethoxazole; Tramadol HCL; Metoclopramide
Possible Neulasta side effects in 75 year old female
Reported by a physician from United Kingdom on 2012-03-28
Patient: 75 year old female
Reactions: White Blood Cell Count Decreased, Monocyte Count Decreased, Band Neutrophil Count Increased, Drug Ineffective, Neutropenic Sepsis, Monocyte Count Increased, Haemoglobin Decreased, Haematocrit Decreased, RED Blood Cell Count Decreased, Platelet Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 85 mg; iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Cyclophosphamide
Dosage: 7300 mg; iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-23
End date: 2011-06-09
Vinorelbine
Dosage: 2 mg; iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Neulasta
Dosage: 6 mg; sc
Indication: Prophylaxis
Start date: 2011-06-15
Rituximab (Rituximab)
Dosage: 650 mg; iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Possible Neulasta side effects in 75 year old female
Reported by a physician from Denmark on 2012-03-19
Patient: 75 year old female
Reactions: White Blood Cell Count Decreased, Monocyte Count Decreased, Band Neutrophil Count Increased, Drug Ineffective, Neutropenic Sepsis, Haemoglobin Decreased, Haematocrit Decreased, RED Blood Cell Count Decreased, Platelet Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 7300 mg, iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Neulasta
Dosage: 6 mg, sc
Indication: Prophylaxis
Start date: 2011-06-15
Rituximab (Rituximab)
Dosage: 650 mg, iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Doxorubicin HCL
Dosage: 85 mg, iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Vinorelbine
Dosage: 2 mg,
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Possible Neulasta side effects in male
Reported by a physician from Germany on 2012-03-14
Patient: male
Reactions: Haemoglobin Decreased, White Blood Cell Count Decreased, Platelet Count Decreased, Skin Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neulasta
Dosage: 6 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-06
Rituximab
Dosage: 750 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-01
Vincristine
Dosage: 2 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-02
Cyclophosphamide
Dosage: 1500 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-02
Doxorubicin HCL
Dosage: 100 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-02-02
Prednisolone
Dosage: 100 mg, unk
Administration route: Oral
Indication: B-Cell Lymphoma
Start date: 2012-02-02
Other drugs received by patient: Acyclovir; Electrolytes NOS W / Macrogol 3350; MST / 00036302 /; Rulid; Pantozol / 01263204 /
Possible Neulasta side effects in 54 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-07
Patient: 54 year old female, weighing 68.1 kg (149.7 pounds)
Reactions: White Blood Cell Count Decreased, Anaemia, Platelet Count Decreased, Febrile Neutropenia
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Abraxane
Dosage: 80 milligram/sq. meter
Start date: 2011-10-13
Carboplatin
Dosage: 6 dosage forms
Indication: Breast Cancer
Start date: 2011-08-11
Doxorubicin HCL
Dosage: 60 milligram/sq. meter
Indication: Breast Cancer
Start date: 2011-11-10
Cyclophosphamide
Dosage: 600 milligram/sq. meter
Indication: Breast Cancer
Start date: 2011-11-10
Abraxane
Dosage: 80 milligram/sq. meter
Indication: Breast Cancer
Start date: 2011-08-11
End date: 2011-10-06
Neulasta
Indication: Chemotherapy
Bevacizumab
Dosage: 10 milligram/kilogram
Indication: Breast Cancer
Start date: 2011-08-11
Possible Neulasta side effects in 75 year old female
Reported by a physician from United Kingdom on 2012-03-05
Patient: 75 year old female
Reactions: White Blood Cell Count Decreased, Haemoglobin Decreased, Haematocrit Decreased, RED Blood Cell Count Decreased, Drug Ineffective, Neutropenic Sepsis, Platelet Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Dosage: 85 mg;iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Vinorelbine
Dosage: 2 mg;iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Rituximab (Rituximab)
Dosage: 650 mg;iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Neulasta
Dosage: 6 mg;sc
Indication: Prophylaxis
Start date: 2011-06-15
Cyclophosphamide
Dosage: 7300 mg;iv
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2011-05-24
End date: 2011-06-09
Possible Neulasta side effects in female
Reported by a individual with unspecified qualification from United States on 2012-02-27
Patient: female, weighing 80.0 kg (176.0 pounds)
Reactions: White Blood Cell Count Decreased, Neutrophil Count Decreased
Drug(s) suspected as cause:
Ifosfamide
Dosage: 10.8 g
Neulasta
Dosage: 6 mg
Taxol
Dosage: 319 mg
Possible Neulasta side effects in 42 year old female
Reported by a physician from United States on 2012-02-07
Patient: 42 year old female
Reactions: White Blood Cell Count Decreased, Incorrect Route of Drug Administration, Nasopharyngitis, Injection Site Haematoma, Arthralgia, Pain, Influenza
Drug(s) suspected as cause:
Neulasta
Other drugs received by patient: Amrubicin
Possible Neulasta side effects in male
Reported by a pharmacist from United States on 2012-02-06
Patient: male
Reactions: White Blood Cell Count Decreased, Bronchitis Viral
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neupogen
Indication: Neutropenia
Neulasta
Indication: Neutropenia
Possible Neulasta side effects in 44 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-02-01
Patient: 44 year old female, weighing 119.6 kg (263.1 pounds)
Reactions: White Blood Cell Count Decreased, Diarrhoea, Lymphatic Disorder, Anaemia, Platelet Count Decreased, Febrile Neutropenia, Cardiac Disorder
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Bevacizumab
Dosage: 10 milligram/kilogram
Indication: Breast Cancer
Start date: 2011-03-24
Doxorubicin HCL
Dosage: 10 milligram/sq. meter
Start date: 2011-03-24
Cyclophosphamide
Dosage: 600 milligram/sq. meter
Indication: Breast Cancer
Start date: 2011-03-24
Abraxane
Dosage: 80 milligram/sq. meter
Indication: Breast Cancer
Start date: 2011-03-24
Neulasta
Dosage: 6 milligram
End date: 2011-08-25
Other drugs received by patient: Metoprolol Tartrate; Famotidine; Guaifenesin; Zolpidem; Cefepime; Fluconazole; Prochlorperazine; Bacitracin; Whole Blood; Benzonatate; Acetaminophen
Possible Neulasta side effects in male
Reported by a pharmacist from United States on 2012-02-01
Patient: male
Reactions: White Blood Cell Count Decreased, Bronchitis Viral
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neupogen
Indication: Neutropenia
Neulasta
Indication: Neutropenia
Possible Neulasta side effects in 44 year old female
Reported by a physician from United States on 2012-01-30
Patient: 44 year old female, weighing 119.6 kg (263.1 pounds)
Reactions: White Blood Cell Count Decreased, Type 2 Diabetes Mellitus, Lymphatic Disorder, Anaemia, Pancytopenia, Febrile Neutropenia, Cardiac Disorder, Diarrhoea, Platelet Count Decreased
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 10 milligram/kilogram
Indication: Breast Cancer
Start date: 2011-03-24
Neulasta
Dosage: 6 milligram
Indication: Breast Cancer
End date: 2011-08-25
Abraxane
Dosage: 80 milligram/kilogram
Indication: Breast Cancer
Start date: 2011-03-24
Bevacizumab
Dosage: 10 milligram/kilogram
Indication: Breast Cancer
Start date: 2011-03-24
Cyclophosphamide
Dosage: 600 milligram/kilogram
Indication: Breast Cancer
Start date: 2011-03-24
Other drugs received by patient: Ambien; Pepcid; Mucinex; Tessalon; Toprol-XL; Bacitracin; Prochlorperazine; Armodafinil; Acetaminophen; Cefepime
Possible Neulasta side effects in 54 year old female
Reported by a physician from United States on 2012-01-30
Patient: 54 year old female, weighing 68.0 kg (149.6 pounds)
Reactions: White Blood Cell Count Decreased, Anaemia, Platelet Count Decreased, Febrile Neutropenia
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Paclitaxel
Dosage: 80 mg/m2, per chemo regim
Indication: Breast Cancer
Start date: 2011-08-11
Cyclophosphamide
Dosage: 600 mg/m2, per chemo regim
Indication: Breast Cancer
Neulasta
Indication: Chemotherapy
Bevacizumab
Dosage: 10 mg/kg, per chemo regim
Indication: Breast Cancer
Start date: 2011-08-11
Carboplatin
Dosage: 6 df, per chemo regim
Indication: Breast Cancer
Start date: 2011-08-11
Doxorubicin HCL
Dosage: 60 mg/m2, per chemo regim
Indication: Breast Cancer
Possible Neulasta side effects in 75 year old female
Reported by a health professional (non-physician/pharmacist) from Germany on 2011-12-12
Patient: 75 year old female, weighing 52.0 kg (114.4 pounds)
Reactions: Emphysema, White Blood Cell Count Decreased, Anaemia, Bone Pain, Febrile Neutropenia, Pyrexia, Somnolence, Ascites, Psoas Abscess, Bronchiectasis, Alopecia, Haemangioma, Clostridial Infection, White Blood Cell Count Increased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neulasta
Other drugs received by patient: Echinacea / 01323501 /; Phosphorus; Helleborus Niger Extract; Plumbum Metallicum; Argentum Metallicum; Homeopatics NOS; Homeopathic Preparation; Mistletoe; Arsenic Trioxide; Helixor; Urtica Extract
Possible Neulasta side effects in 54 year old female
Reported by a health professional (non-physician/pharmacist) from Netherlands on 2011-12-08
Patient: 54 year old female
Reactions: Pharyngeal Inflammation, White Blood Cell Count Decreased, Chest Discomfort, Nausea, Alanine Aminotransferase Increased, Platelet Count Increased, Haemoglobin Decreased, Dizziness
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Adriamycin PFS
Dosage: 95 mg, unk
Indication: Breast Cancer
Start date: 2011-07-22
End date: 2011-07-22
Cyclophosphamide
Dosage: 950 mg, unk
Indication: Breast Cancer
Start date: 2011-07-22
End date: 2011-07-22
Zometa
Dosage: 4 mg, unk
Indication: Breast Cancer
Start date: 2011-07-22
End date: 2011-07-22
Neulasta
Taxotere
Dosage: 140 mg, unk
Indication: Breast Cancer
Start date: 2011-07-22
End date: 2011-07-22
Other drugs received by patient: Granisetron; Ondansetron; Dexamethasone
Possible Neulasta side effects in 44 year old female
Reported by a individual with unspecified qualification from United States on 2011-11-17
Patient: 44 year old female, weighing 119.5 kg (262.9 pounds)
Reactions: White Blood Cell Count Decreased, Diarrhoea, Lymphatic Disorder, Anaemia, Febrile Neutropenia, Platelet Count Decreased, White Blood Cell Count, Cardiac Disorder
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: over 5-30 min on day 1 of wks 13, 15, 17 and 19. total dose: 130 mg. last dose prior sae 30 jun 2011
Indication: Breast Cancer
Neulasta
Dosage: last date administered 25 august 2011
Indication: Product Used FOR Unknown Indication
Doxorubicin HCL
Dosage: over 5-30 min on day 1 of wks 13, 15, 17 and 19. total dose: 106 mg. last dose prior sae 25 aug 2011
Cyclophosphamide
Dosage: over 5-30 min on day 1 of wks 13, 15, 17 and 19. total dose: 1055 mg.
Paclitaxel
Dosage: over 1hour on 1 day of weeks 1-12. last dose prior to sae 09 jun 2011.
Indication: Breast Cancer
Avastin
Dosage: over 30-90 minutes on 1 day of weeks 1,3,5,7,9,11,13,15 and 17, dose: 1200 mg. dose increased.
Indication: Breast Cancer
Avastin
Dosage: over 30-90 minutes on 1 day of weeks 1,3,5,7,9,11,13,15 and 17, dose: 1200 mg. dose reduced.
Cyclophosphamide
Dosage: over 5-30 min on day 1 of wks 13, 15, 17 and 19. total dose: 1300 mg.
Indication: Breast Cancer
Paclitaxel
Dosage: over 1hour on 1 day of weeks 1-12.
Other drugs received by patient: Cefepime; Mucinex; Ambien; Pepcid; Prochlorperazine; Acetaminophen; Tessalon; Toprol-XL; Diflucan; Bacitracin
Possible Neulasta side effects in 44 year old female
Reported by a individual with unspecified qualification from United States on 2011-11-04
Patient: 44 year old female, weighing 119.5 kg (262.9 pounds)
Reactions: White Blood Cell Count Decreased, Lymphatic Disorder, Anaemia, Febrile Neutropenia, White Blood Cell Count, Cardiac Disorder, Diarrhoea, Platelet Count Decreased
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Neulasta
Dosage: last date administered 25 august 2011
Indication: Product Used FOR Unknown Indication
Doxorubicin HCL
Dosage: over 5-30 min on day 1 of wks 13, 15, 17 and 19. total dose: 130 mg. last dose prior sae 30 jun 2011
Indication: Breast Cancer
Doxorubicin HCL
Dosage: over 5-30 min on day 1 of wks 13, 15, 17 and 19. total dose: 106 mg. last dose prior sae 25 aug 2011
Avastin
Dosage: over 30-90 minutes on 1 day of weeks 1,3,5,7,9,11,13,15 and 17, dose: 1200 mg. dose increased.
Indication: Breast Cancer
Cyclophosphamide
Dosage: over 5-30 min on day 1 of wks 13, 15, 17 and 19. total dose: 1055 mg.
Paclitaxel
Dosage: over 1hour on 1 day of weeks 1-12. last dose prior to sae 09 jun 2011.
Indication: Breast Cancer
Avastin
Dosage: over 30-90 minutes on 1 day of weeks 1,3,5,7,9,11,13,15 and 17, dose: 1200 mg. dose reduced.
Cyclophosphamide
Dosage: over 5-30 min on day 1 of wks 13, 15, 17 and 19. total dose: 1300 mg.
Indication: Breast Cancer
Paclitaxel
Dosage: over 1hour on 1 day of weeks 1-12.
Other drugs received by patient: Prochlorperazine; Ambien; Pepcid; Tylenol-500; Cefepime; Mucinex; Diflucan; Tessalon; Bacitracin; Toprol-XL
Possible Neulasta side effects in female
Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-26
Patient: female
Reactions: White Blood Cell Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Neulasta
Indication: Chemotherapy
Start date: 2011-01-01
Neupogen
Dosage: unk
Indication: Neutropenia
Start date: 2011-01-01
Other drugs received by patient: Bendamustine; Rituxan
Possible Neulasta side effects in
Reported by a pharmacist from Germany on 2011-10-25
Patient:
Reactions: White Blood Cell Count Decreased
Drug(s) suspected as cause:
Neulasta
Other drugs received by patient: Antineoplastic Agents
Page 1 Next >>
|
